# MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma

> **NCT04013334** · PHASE2 · UNKNOWN · sponsor: **Momotaro-Gene Inc.** · enrollment: 12 (actual)

## Conditions studied

- Malignant Pleural Mesothelioma

## Interventions

- **DRUG:** MTG201
- **DRUG:** Nivolumab Injection [Opdivo]

## Key facts

- **NCT ID:** NCT04013334
- **Lead sponsor:** Momotaro-Gene Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-08-15
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-01-01
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2022-06-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04013334

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04013334, "MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04013334. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*